IGMS vs. ALLO, INZY, TNXP, LIMN, CADL, PVLA, DBVT, SGMT, IMMP, and ACB
Should you be buying IGM Biosciences stock or one of its competitors? The main competitors of IGM Biosciences include Allogene Therapeutics (ALLO), Inozyme Pharma (INZY), Tonix Pharmaceuticals (TNXP), Liminatus Pharma (LIMN), Candel Therapeutics (CADL), Palvella Therapeutics (PVLA), DBV Technologies (DBVT), Sagimet Biosciences (SGMT), Prima BioMed (IMMP), and Aurora Cannabis (ACB). These companies are all part of the "pharmaceutical products" industry.
IGM Biosciences vs. Its Competitors
IGM Biosciences (NASDAQ:IGMS) and Allogene Therapeutics (NASDAQ:ALLO) are both small-cap medical companies, but which is the superior investment? We will contrast the two businesses based on the strength of their institutional ownership, media sentiment, dividends, analyst recommendations, earnings, risk, profitability and valuation.
In the previous week, IGM Biosciences had 5 more articles in the media than Allogene Therapeutics. MarketBeat recorded 6 mentions for IGM Biosciences and 1 mentions for Allogene Therapeutics. IGM Biosciences' average media sentiment score of 0.51 beat Allogene Therapeutics' score of 0.00 indicating that IGM Biosciences is being referred to more favorably in the media.
42.8% of IGM Biosciences shares are owned by institutional investors. Comparatively, 83.6% of Allogene Therapeutics shares are owned by institutional investors. 57.0% of IGM Biosciences shares are owned by company insiders. Comparatively, 13.2% of Allogene Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.
IGM Biosciences has a beta of 0.48, indicating that its share price is 52% less volatile than the S&P 500. Comparatively, Allogene Therapeutics has a beta of 0.31, indicating that its share price is 69% less volatile than the S&P 500.
IGM Biosciences presently has a consensus price target of $5.50, indicating a potential upside of 307.41%. Allogene Therapeutics has a consensus price target of $8.44, indicating a potential upside of 627.97%. Given Allogene Therapeutics' stronger consensus rating and higher probable upside, analysts clearly believe Allogene Therapeutics is more favorable than IGM Biosciences.
Allogene Therapeutics has a net margin of 0.00% compared to IGM Biosciences' net margin of -7,417.79%. Allogene Therapeutics' return on equity of -52.98% beat IGM Biosciences' return on equity.
IGM Biosciences has higher revenue and earnings than Allogene Therapeutics. Allogene Therapeutics is trading at a lower price-to-earnings ratio than IGM Biosciences, indicating that it is currently the more affordable of the two stocks.
Summary
Allogene Therapeutics beats IGM Biosciences on 9 of the 16 factors compared between the two stocks.
Get IGM Biosciences News Delivered to You Automatically
Sign up to receive the latest news and ratings for IGMS and its competitors with MarketBeat's FREE daily newsletter.
New MarketBeat Followers Over Time
This chart shows the number of new MarketBeat users adding IGMS and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Media Sentiment Over Time
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
IGM Biosciences Competitors List
Related Companies and Tools
This page (NASDAQ:IGMS) was last updated on 7/7/2025 by MarketBeat.com Staff
